ACS Med Chem Lett Impact Factor 2025: What You Need to Know
ACS Medicinal Chemistry Letters (ACS Med Chem Lett) had a 2021 impact factor of 4.632. That number places it as a solid mid-tier journal in the medicinal chemistry field. For researchers deciding where to submit their work, the impact factor is one useful data point. Here is what that number means, how it compares to other journals, and what else you should consider.
What the Impact Factor Represents
The impact factor is a yearly metric calculated by Clarivate Clarivate. It measures the average number of citations received in a given year by articles published in the journal during the two preceding years. For ACS Med Chem Lett, the 2021 figure of 4.632 means that articles published in 2019 and 2020 were cited, on average, roughly 4.6 times during 2021.
A few things to keep in mind about this number:
- It is a journal-level metric, not an article-level one. A single paper might be cited 50 times, while another is cited once.
- It can fluctuate year to year based on special issues or hot topics.
- It does not measure quality or rigor directly. It measures citation activity, which is influenced by the size of the research community in that subfield.
For a journal that started in 2009 Wikipedia — ACS Medicinal Chemistry Letters, an impact factor in the mid-4s is respectable. It shows the journal has established a stable readership within medicinal chemistry.
How It Compares to Other Journals
Medicinal chemistry journals cover a wide range of impact factors:
- Journal of Medicinal Chemistry (ACS): impact factor around 7-8. The flagship journal with high selectivity.
- European Journal of Medicinal Chemistry: impact factor around 6-7. A large European journal with broad scope.
- Bioorganic & Medicinal Chemistry Letters: impact factor around 2.5-3. A competitor that also publishes short communications.
- ACS Medicinal Chemistry Letters: impact factor of 4.632. It sits between the top-tier JMC and the lower-tier BMC Letters.
If your work is a major breakthrough with broad implications, aim for JMC. If it is a solid but incremental piece of medicinal chemistry, ACS Med Chem Lett is a strong target. It offers faster publication than JMC in many cases and focuses on short, concise reports.
What the Journal Publishes
The journal covers drug design, synthesis, biological evaluation, and structure-activity relationships American Chemical Society. It is edited by Dennis C. Liotta of Emory University Wikipedia — ACS Medicinal Chemistry Letters. Most articles are short communications or letters, not full research papers. This format suits researchers who want to get a result out quickly.
How the Journal’s Scope Shapes Its Citation Profile
The journal’s focus on short, rapid communications affects citation patterns. A letter describing a new compound series can be read quickly and cited soon after publication. This speed of consumption can boost citation counts compared to longer papers. But letters sometimes provide less experimental detail, which can make them less useful as primary references for methods sections.
For example, a letter reporting a new class of kinase inhibitors might get cited quickly by groups working on similar targets. A full paper in JMC with extensive selectivity data and in vivo results might accumulate more citations over a longer period. The impact factor captures the average of these two dynamics.
Citation Half-Life
The cited half-life measures the median age of articles cited in a given year. For ACS Med Chem Lett, it is relatively short, typically around 5-6 years. That is normal for a letters journal. Most citations come from recent articles, not from papers published a decade ago. Compare this to JMC, which has a cited half-life of 8-10 years. If you want rapid visibility and quick citations from peers, a letters journal works well. If you expect your paper to be cited for many years, a full-paper journal might be a better fit.
Practical Implications for Authors
When deciding whether to submit to ACS Med Chem Lett, consider these concrete factors:
Time to First Decision
The journal aims for a first decision within 2-3 weeks. That is faster than many full-paper journals, which can take 6-8 weeks. For a graduate student or postdoc who needs to graduate or apply for a job, that speed matters.
Article Processing Charges
ACS Med Chem Lett is a subscription journal, not open access by default. If you want open access, you pay an article processing charge of roughly $2,500-3,000. Some funders require open access, so factor that cost into your decision.
Format Requirements
Letters are typically 4-5 journal pages, which translates to roughly 2,500-3,000 words of main text plus figures and tables. You cannot include extensive experimental sections. Supporting information is published online only. If your work requires detailed synthetic procedures, you need to be comfortable putting that in the supporting information file.
Revision Policy
The journal typically allows one round of major revision. If reviewers ask for substantial new data, you have about 30 days to provide it. If you cannot address the concerns, the paper is rejected. This is stricter than some journals that allow multiple revision rounds. Submit only when your data are complete.
Key Takeaways
- ACS Med Chem Lett had a 2021 impact factor of 4.632, placing it solidly in the middle of medicinal chemistry journals.
- The impact factor is a useful but limited metric; it measures average citations per article, not article quality.
- The journal is a good fit for short, focused reports on drug design and synthesis, with faster publication times than top-tier journals.
- The citation half-life is short (5-6 years), making it best for current, fast-moving topics.
- First decision times are fast (2-3 weeks), which helps authors on tight timelines.
- Article processing charges apply for open access, typically $2,500-3,000.
- Strict length limits mean you must use supporting information for detailed methods.
- The revision policy allows one major revision round, so submit only when data are complete.
